Next Article in Journal
The Future of Minimally Invasive Capsule Panendoscopy: Robotic Precision, Wireless Imaging and AI-Driven Insights
Next Article in Special Issue
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors
Previous Article in Journal
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Previous Article in Special Issue
Precision Medicine: Disease Subtyping and Tailored Treatment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 24
10.3390/cancers15245860
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2019, 11(8), 1093.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093

by
Mohammad Krayem
1,2,*,
Malak Sabbah
1,
Ahmad Najem
1,
An Wouters
3,
Filip Lardon
3,
Stephane Simon
2,
François Sales
1,
Fabrice Journe
1,4,
Ahmad Awada
1,5,
Ghanem E. Ghanem
1 and
Dirk Van Gestel
2
1
Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger-Bordet 1, 1000 Brussels, Belgium
2
Department of Radiation Oncology, Institut Jules Bordet, Université libre de Bruxelles, 1000 Brussels, Belgium
3
Center for Oncological Research (CORE), University of Antwerp, 2610 Wilrijk, Belgium
4
Department of Human Anatomy and Experimental Oncology, Université de Mons (UMons), Research Institute for Health Sciences and Technology, 7000 Mons, Belgium
5
Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(24), 5860; https://doi.org/10.3390/cancers15245860
Submission received: 25 October 2023 / Accepted: 14 November 2023 / Published: 15 December 2023
(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
Versions Notes
In the original article [1], there was a mistake in Figure 2A as published. The actin blot in our publication in Cancers (Figure 2A) had already been used in our published paper in Oncotarget in 2018. This is probably due to an error in our image saving. Note that this mistake does not change or alter the content and conclusions of our paper. The mistake indeed concerns control experiments, which were very easily reproduced. The corrected Figure 2A appears below.
Cancers 15 05860 i001
In Figure 2B’s P53 panel, there are vertical splices between lanes 4/5 and 12/13. There are no apparent splices between these lanes in the other panels. This is because samples for every group (i.e., four conditions) were conducted on different membranes.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Krayem, M.; Sabbah, M.; Najem, A.; Wouters, A.; Lardon, F.; Simon, S.; Sales, F.; Journe, F.; Awada, A.; Ghanem, G.E.; et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Krayem, M.; Sabbah, M.; Najem, A.; Wouters, A.; Lardon, F.; Simon, S.; Sales, F.; Journe, F.; Awada, A.; Ghanem, G.E.; et al. Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. Cancers 2023, 15, 5860. https://doi.org/10.3390/cancers15245860

AMA Style

Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem GE, et al. Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. Cancers. 2023; 15(24):5860. https://doi.org/10.3390/cancers15245860

Chicago/Turabian Style

Krayem, Mohammad, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E. Ghanem, and et al. 2023. "Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093" Cancers 15, no. 24: 5860. https://doi.org/10.3390/cancers15245860

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop